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Molecular identification 
and antibiotic resistance pattern 
of actinomycetes isolates 
among immunocompromised 
patients in Iran, emerging of new 
infections
Hossein Ali Rahdar1, Shahram Mahmoudi2, Abbas Bahador3, Fereshteh Ghiasvand4, 
Fatemah Sadeghpour Heravi5 & Mohammad Mehdi Feizabadi3,6*
Recent advancements in DNA-based approaches have led to the identification of uncommon and 
rare bacterial pathogens. In this study, by utilizing a DNA-based approach, a total of 1043 clinical 
specimens were processed for the identification of actinobacteria targeting the 16S rRNA and gyrB 
genes. Drug susceptibility testing was also conducted using micro-broth dilution and PCR. Two 
isolates of Nocardia flavorosea and Rhodococcus erythropolis were reported for the first time in Iran. 
Also, Nocardiopsis dassonvillei, Streptomyces olivaceus, and Streptomyces griseus were reported for 
the first time in Asia. Infections caused by Nocardia caishijiensis and Prauserella muralis have also been 
reported in this study. The first Asian case of pulmonary infection caused by Nocardia ignorata and the 
first global case of brain abscess caused by Nocardia ninae and Nocardia neocaledoniensis have been 
reported in this study. Overall 30 isolates belonging to 6 genera (Nocardia, Streptomyces, Rodoccoccus, 
Nocardiopsis, Rothia, and Prauserella) were detected in 30 patients. All 30 isolates were susceptible 
to amikacin and linezolid. Three isolates including Nocardia otitidiscaviarum (n = 2) and Nocardia 
flavorosea (n = 1) were resistant to trimethoprim-sulfamethoxazole which were the first trimethoprim-
sulfamethoxazole resistant clinical actinomycetes in Iran. Isolation of rare species of actinomycetes 
particularly Nocardia spp. requires urgent action before they spread clinically particularly among 
immunocompromised patients.
Actinomycetales order mainly known as aerobic actinomycetes are Gram-positive bacteria with a high guanine-
plus-cytosine (GC) content in their  genomes1. Bacterial classification based on cellular compositions such as 
meso or diaminopimelic acid, sugars, and long-range mycolic acid is the main method of classification in this 
group of  bacteria1. Despite their low prevalence in clinical specimens, Actinomycetales can cause life-threatening 
infections in susceptible individuals like transplant recipients, patients receiving immunosuppressive drugs, and 
those with HIV, cancer, and diabetes, as well as in  animals2–7. Depending on the site of entry and the host immune 
system, these pathogens may cause severe complications in affected individuals.
Actinomycetes infections may result in non-specific clinical symptoms such as granuloma and/or abscess 
 formation2–5. Sample collection in actinomycetes-related infections is performed by invasive methods such as 
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biopsy or bronchial  wash6,7. Since these bacteria share several common phenotypic and chemical characteristics, 
molecular-based methods have been recently utilized for precise  identification8.
Accurate identification and antibiotic susceptibility testing of actinomycete isolates especially from diffused 
infections and brain abscesses may help reduce mortality and the financial burden associated with actinomycetes-
related infections as well as antimicrobial  resistance9,10. Transformation of actinomycetes from an environmental 
saprophyte to a real pathogen is of primary importance particularly in vulnerable  populations11,12. Due to the 
increased number of immunocompromised patients, opportunistic pathogens are the major leading cause of 
mortality in this  group4,5,13–17. Fatal infections caused by these bacteria have been reported in immunocompetent 
 individuals9,18,19. Treatment of these infections is a challenging approach and may last from months to  years4,11. 
In this regard, treatment failure is also a common outcome and could result in the recurrence of the disease and 
 death20–22.
The mortality associated with actinomycetal infections in transplant recipients and immunodeficient patients 
was reported as high as 3.5 times that of other bacterial  infections23,24. Therefore, accurate and rapid identification 
of clinically important bacterial genera and species can help to manage the infection in a timely manner. Due to 
the paucity of information on the prevalence, species distribution, and drug-resistance of actinomycetes in Asia, 
particularly in developing countries such as Iran, we are aiming at providing useful information in this regard.
Materials and method
Study design and ethical statements. The present cross-sectional study was carried out at the teach-
ing hospital of Tehran University of Medical Sciences, Tehran, Iran, from May 2017 to October 2019. This 
study was approved by the ethics committee of Tehran University of Medical Science (IR.TUMS.MEDICINE.
REC.1397.261). All the experiments were performed in accordance with relevant guidelines and regulations. 
Informed consent was obtained for this study.
Patients and specimens. A total of 1043 consecutive non-duplicate clinical samples including sputum, 
bronchoalveolar lavage (BAL), blood, drainage of the brain, or cutaneous abscesses and corneal scraping sus-
pected to be actinomycetes infections were collected from patients in this study. The specimens were then trans-
ferred to the microbiology laboratory while observing standard safety protocols.
Recruited patients had the following inclusion criteria: (1) at least one underlying condition supporting 
infection by actinomycetes such as HIV infection, cancer, diabetes, autoimmune disorders, transplantation, 
immunodeficiency and chronic respiratory complications, (2) clinical or radiological findings consistent with 
a diagnosis of infection by actinomycetes such as lung consolidation, nodule, and cavitation in radiography, 
cutaneous lesions, solid and soft organ abscess. Patients with previous antibiotic therapy and those with evidence 
of tuberculosis or non-tuberculosis mycobacterial infections as well as fungal infections were excluded from 
the experiment.
Isolation of actinomycetes. The direct microscopical examination was performed using gram and partial 
acid-fast staining. Specimens were cultured on blood and chocolate agar plates containing cycloheximide, van-
comycin, and polymyxin B as well as antibiotic-free  media7,11,12. After 3 weeks of incubation at 37 °C, suspicious 
colonies were selected for further investigation. Conventional biochemical tests including hydrolysis of hypox-
anthine, tyrosine and xanthine, resistance to lysozyme, growth at 45 °C were performed and the colony mor-
phology were assessed. Using these phenotypic tests, identification of Nocardia spp. at genus level was  done11,12. 
Because phenotypic identification of all Actinomycetales is not feasible, suspicious colonies other than Nocardia 
were directly subjected to molecular identification.
Molecular identification. Bacterial DNA was extracted using the boiling  method12. In brief, PCR test was 
performed using primers 27F: 5′-AGA GTT TGA TCC TGG CTC AG-3′ and 1525R: 5′-AAG GAG GTG WTC 
CAR CC-3′13 targeting 16S rRNA gene as the primary target for identification. For rare Nocardia species, a frag-
ment of gyrB gene, as a confirmatory target, was amplified and sequenced using primers F: 5’-CTT CGC CAA 
CAC CAT CAA CAC-3’ and R: 5’-TGA TGA TCG ACT GGA CCT CG-3′13. PCR reactions were performed in 
a mixture of 25 μL containing 12.5 μL of the master mix, (Thermo Fisher Scientific, USA), 1 μL (0.2 µM) of each 
forward and reverse primers and 1 μL template DNA under following conditions: 5 min of preheating at 94 °C, 
32 cycles of 30 s denaturation at 95 °C, 30 s of primer annealing at 58.5 °C, 1 min extension step at 72 °C and 
post cycling extension of 5 min at 72 °C. The process of amplification was carried out in a thermal cycler (Biorad 
Thermal Cycler, USA)25.
Electrophoresis of PCR products was performed in 1% agarose gel prepared in 1 × TAE buffer with 100 mV 
for 30 min. Initial quality assessment of PCR products (single and sharp bands) was performed using a UV tran-
silluminator. The amplicons were subsequently sent for sequencing using both primers (Bioneer, South Korea). 
Results were trimmed and aligned with verified sequences in GenBank using the Basic Local Alignment Search 
Tool (BLAST). Standard databases for Nucleotide collection (nr/nt) and Highly similar sequences (megablast) 
program were used for alignment (https:// blast. ncbi. nlm. nih. gov/ Blast).
Antimicrobial susceptibility testing. Drug susceptibility test was performed using the broth microdilu-
tion method in accordance with the CLSI M24-A2 guideline. Tested antibiotics were amikacin (1–64 μg/mL), 
amoxicillin-clavulanic acid (2/1–64/32 μg/mL), cefepime (1–32 μg/mL), ceftriaxone (4–64 μg/mL), ciprofloxa-
cin (0.12–4 μg/mL), doxycycline (2–64 μg/mL), imipenem (2–64 μg/mL), linezolid (1–32 μg/mL), minocycline 
(1–8 μg/mL) and trimethoprim/sulfamethoxazole (TMP-SXT) (0.25/4.75–8/152 μg/mL). For isolates of Rhodo-
coccus and Rothia, similar to previous  studies26–28, different panels of antibiotics were tested. Serial dilutions of 
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each antibiotic were made in 96-well microplates. Isolates were suspended in 200 μL of sterile water to prepare 
homogeneous suspensions of the bacteria. After adjustment to 0.5 McFarland standard turbidity, 50 μL of the 
solution was transferred into 10 mL of Mueller–Hinton broth and then added to each well of the micro-plate. 
After 48 to 72 h of incubation at 37 °C, MIC values were calculated and interpreted as susceptible (S), intermedi-
ate (I) or resistant (R) according to the  CLSI26. Nocardia transvalensis NRRL B-10637 and Nocardia asteroides 
ATCC 19247 were served as control strains and incubated for 96 h for acceptable growth exhibition.
Detection of TMP-SXT resistance genes (sulf, int, and DfrA). PCR was performed using specific 
primers to detect TMP-SXT resistance genes (sulf1-sulf2, int1-int3, and DfrA) as described  previously26. The 
PCR products were visualized by electrophoresis in 1% agarose gel in 1 × TBE (Tris/Borate/EDTA) buffer, stained 
with safe stain load dye (CinnaGen Co. Tehran, Iran) under ultraviolet illumination. Results were interpreted 
based on the amplicon size as described  previously26. To ensure the correctness of our results, Staphylococcus 
epidermidis ATCC 12228, Vibrio cholerae O1 strain SK-10, E. coli strain having a R483, E. coli strain having a 
pSMB731, and E. coli strain AMR 130 were used as positive controls for dfrA, int1, int2, int3 and sulf 1 and 2, 
respectively (Fig. 1).
Figure 1.  Gel electrophoresis of dfrA gene (panel A, PC: Staphylococcus epidermidis ATCC 12228), sulf2 gene 
(panel B, PC: Escherichia coli strain AMR 130), sulf1 gene (panel C, PC: Escherichia coli strain AMR 130, 1: 
Nocardia otitidiscaviarum, 2: Nocardia flavorosea), int1 gene (panel D, PC: Vibrio cholerae O1 strain SK-10, 1: 
Nocardia otitidiscaviarum, 2: Nocardia flavorosea, 3: Nocardia otitidiscaviarum), int2 gene (panel E, PC: E. coli 
strain having a R483), and int3 gene (panel F, PC: E. coli strain having a pSMB731) PCR products. M Marker, 
PC positive control, NC negative control.
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Result
Based on the culture result, out of 1043 patients, 30 cases of actinomycetes infections (2.88%) were diagnosed. 
Of these, 22 (73.33%) and 8 (26.67%) were identified in males and females, respectively with a mean age of 
55.43 ± 13.39 years old. Except for 2 healthy cases (6.67%), other cases had underlying medical conditions such 
as HIV/AIDS (n = 8), transplantation (n = 5), malignancy (n = 5), pemphigus vulgaris (n = 4), diabetes (n = 4) 
and corticosteroid therapy (n = 2). Involvement of the lungs was the most common form of infection (n = 24, 
80%), followed by brain abscess (n = 3, 10%), cutaneous abscess (n = 1, 3.33%), arthritis (n = 1, 3.33%), and 
sepsis (n = 1, 3.33%). Two patients (6.67%) died of pulmonary infection and brain abscess before reporting the 
laboratory outcome.
According to patient history, trimethoprim/sulfamethoxazole (n = 19, 63.33%) was the most commonly pre-
scribed antibiotic followed by imipenem (n = 6, 20%), trimethoprim/sulfamethoxazole and imipenem (n = 3, 
10%), amikacin (n = 1, 3.33%), and levofloxacin (n = 1, 3.33%) in this study. Table 1 presents the baseline char-
acteristics and clinical information of the patients.
According to the DNA-based method in this study, the causative agent of 30 cases of actinomycetes belonged 
to 6 genera (Nocardia, Nocardiopsis, Streptomyces, Prauserella, Rhodococcus, and Rothia) and 17 species with the 
dominance of Nocardia cyriacigeorgica (n = 7, 23.33%), followed by Nocardia otitidiscaviarum (n = 4, 13.33%), 
Nocardia asteroides (n = 3, 10%), Nocardia ignorata (n = 2, 6.67%), Nocardiopsis dassonvillei (n = 2, 6.67%) and 1 
isolate (3.33%) from 12 other species including rare pathogens such as Prauserella muralis, Rhodococcus eryth-
ropolis, and Rothia dentocariosa (Table 1; Figs. 2, 3).
All Nocardia isolates (n = 23) were susceptible to amikacin and linezolid, while some were non-susceptible 
(resistant/intermediate) to trimethoprim-sulfamethoxazole (n = 3, 13.04%), imipenem (n = 6, 26.08%), mino-
cycline (n = 6, 39.13%), ceftriaxone (n = 11, 47.83%), doxycycline (n = 11, 47.83%), cefepime (n = 14, 60.87%), 
amoxicillin-clavulanic acid (n = 18, 78.26%), and ciprofloxacin (n = 20, 86.96%). Nocardiopsis dassonvillei isolates 
(n = 2) were non-susceptible to amoxicillin-clavulanic acid (50%), doxycycline (50%), ciprofloxacin (100%), 
ceftriaxone (100%) and cefepime (100%) but susceptible to other antimicrobial drugs.
Streptomyces olivaceus and Streptomyces griseus were non-susceptible to 3 and 4 out of 10 tested antimicrobial 
drugs, respectively. Regarding the rare species Prauserella muralis, Rhodococcus erythropolis, and Rothia dento-
cariosa, a non-susceptible phenotype was observed to 2 out of 10, 5 out of 11 and one out of 8 tested antimicrobial 
drugs, respectively. Susceptibility pattern of all isolates is presented in Table 2.
Due to the common prescription of trimethoprim/sulfamethoxazole in actinomycetes infections, especially 
nocardiosis, resistant isolates to this antibiotic were further studied. A total of 3 isolates including 2 Nocardia 
otitidiscaviarum and one Nocardia flavorosea isolates were resistant to trimethoprim/sulfamethoxazole. Genes 
int1, sulf1 were detected in all three isolates (Fig. 1).
Discussion
Actinomycetes can be isolated from different environmental sources including soil, water, decaying plants, and 
 animals11,12. Unlike many bacterial communities including Bacillus and Clostridium which produce endospore 
as a dormant structure, in actinomycetes, mycolic acid and a peptidoglycan layer form a non-productive and 
tough structure to survive under harsh conditions for a long period of  time29–32.
Immunodeficiency, transplantation procedure, and old age predispose individuals to bacterial infection par-
ticularly caused by opportunistic pathogens. Meanwhile, with the exception of a few studies, a comprehensive 
study on the evaluation of actinomycetes is not available. On the other hand, traditional and culture-based 
methods have inadequacies in the detection of unexpected and rare pathogens such as actinomycetes in clinical 
specimens. Therefore, further investigation using sequencing-based approaches is required to identify actino-
mycetes at species level accurately and evaluate antibiotic resistance patterns in order to prevent the progression 
of infection and extend the current knowledge regarding the epidemiology of  infection13–17,33.
The prevalence of actinomycetes infections varies geographically. In this study, the prevalence of actinomy-
cetes infections was 2.88% (30 out of 1043). The prevalence of Nocardia infections was 2.21% (23 out of 1043) 
which was slightly higher than the estimated prevalence of nocardiosis in Iran (1.88%)34. From 1970 to 2005, the 
prevalence of nocardiosis in Asia has been estimated to range between 0.001% in the United Arab Emirates to 
1.9% in China, while in Africa, it was estimated to be 1.8% in Congo to 4.1% in  Nigeria34. However, due to the 
paucity of information in this regard, almost all the recent studies were focused on previously isolated actino-
mycetes or retrospective reviews of medical records and were unable to provide a comprehensive prevalence of 
the infection. Similar prospective studies are needed to improve our understanding of the exact prevalence of 
actinomycetes in different countries.
In this study, pulmonary infection (n = 24, 80%) was the most common complication among patients and was 
higher than previous reports in Iran (50%)13, the United States (57.4%) and China (65.22%). Extrapulmonary 
infection was found in 6 patients, of them 3 were diagnosed with brain abscess. The brain abscesses made 10% 
of all cases in this study and is close to the previous reports in Iran (9%)13. Based on these results, nocardiosis 
should be considered in all patients with pulmonary infections as the lungs are the most common site of infec-
tion. However, extrapulmonary infections, especially brain abscesses should not be overlooked. Although the 
mortality associated with brain abscesses is high (40–50%), it can also be misdiagnosed with neoplasms, fungal 
or mycobacterial  abscesses19.
Due to the immune deficiency and low CD4+ count, HIV patients are prone to actinomycetes infections. In 
this study, HIV/AIDS was the most common underlying condition which was found in 8 patients (26.67%) and 
was consistent with the previous study in  Iran13. Delayed diagnosis and treatment of actinomycetes infections 
among HIV patients can lead to a high mortality rate from 18 to 66%35.
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forgyrB Treatment OutcomeHYP TYR XAN
1 39/M HIV/AIDS Lung BAL −  + − − −  + Nocardia cyr-iacigeorgica KY817986 − SXT Cured
2 68/M Liver trans-plantation Lung BAL − − − − −  + 
Nocardia 
ignorata KY817987 MT739560 SXT Cured
3 43/M HIV/AIDS Lung BAL − - NA NA NA − Streptomyces olivaceus KY817988 MT739561 IMP Cured
4 29/M HIV/AIDS Lung BAL − - NA NA NA − Prauserella muralis KY817989 − SXT Cured
5 71/F Healthy Lung BAL −  + − − −  + Nocardia cyr-iacigeorgica MH598412 − IMP Cured
6 39/M Leukemia Lung Tracheal aspirate − -  +  +  + -
Nocardiopsis 
dassonvillei MH598413 MT739562 IMP Cured
7 40/M Pemphigus vulgaris Lung BAL −  + − − −  + 
Nocardia cyr-
iacigeorgica MK680074 − SXT Cured
8 41/M Pemphigus vulgaris Lung BAL −  + − − −  + 
Nocardia cyr-
iacigeorgica MK680076 − SXT Cured
9 39/M Pemphigus vulgaris Lung BAL  +  +  + -  +  + 
Nocardia otiti-










Blood Blood − − − − − − Rothia dento-cariosa MK841031 MT739565 LEVO Cured
12 55/M Multiple myeloma Lung BAL − − − − −  + 
Nocardia 





Skin Abscess drainage − −  +  + −  + 
Nocardia brasil-
iensis MK841315 MT739567 SXT Cured
14 34/F Diabetes Lung BAL  + − − − −  + Nocardia asteroides MK841322 - SXT Cured
15 59/F Liver trans-plant Lung BAL −  + −  + −  + 
Nocardia neo-
caledoniensis MK841332 MT739568 SXT Death
16 73/M Healthy Lung BAL −  +  + −  +  + Nocardia otiti-discaviarum MK841414 MT739569 SXT Cured
17 52/F Multiple myeloma Brain
Abscess 
drainage −  +  + −  +  + 
Nocardia otiti-
discaviarum MK841475 MT739570 SXT + IMP Death
18 69/M Lung trans-plantation Lung BAL − − − − −  + 
Nocardia caishi-
jiensis MK875816 MT739571 SXT Cured
19 74/F HIV/AIDS Lung Sputum − − − − −  + Nocardia asteroides MK875969 − SXT Cured






Brain Abscess drainage − −  + − −  + Nocardia ninae MK876369 MT739573 SXT + IMP Cured
22 74/M HIV/AIDS Lung BAL − − − − − − Rhodococcus erythropolis MK876724 − IM Cured
23 61/F Diabetes Lung BAL −  + − − −  + Nocardia cyr-iacigeorgica MK878397 − SXT Cured
24 51/M HIV/AIDS Brain Abscess drainage −  + − − −  + 
Nocardia cyr-
iacigeorgica MK878400 − SXT + IMP Cured
25 43/M Lung trans-plantation Lung
Tracheal 
aspirate −  + − − −  + 
Nocardia cyr-
iacigeorgica MK878402 − SXT Cured
26 57/M Diabetes Lung BAL −  +  + −  +  + Nocardia otiti-discaviarum MK878403 MT739574 AMK Cured
27 65/M Multiple myeloma Lung BAL − − − − −  + 
Nocardia 
asteroides MK878404 − SXT Cured
28 47/M HIV/AIDS Lung Tracheal aspirate −  + − − −  + 
Nocardia 
flavorosea MK878408 MT739575 SXT Cured
29 73/M Diabetes Joint Synovial fluid  + − NA NA NA −
Streptomyces 
griseus MK878410 − IMP Cured
30 71/M Leukemia Lung BAL − −  +  +  + − Nocardia das-sonvillei MK878413 MT739576 IMP Cured
Table 1.  Baseline characteristics of patients, underlying conditions, laboratory findings, causative agents, 
treatment and outcome of 30 cases of actinomycetes infection. M male, F female, BAL bronchoalveolar lavage, 
HYP hypoxanthine, TYR tyrosine, XAN xanthine, LYS lysozyme, SXT trimethoprim/sulfamethoxazole, IMP 
imipenem, LEVO levofloxacin, AMK amikacin, NA not applicable.
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Less severe diseases can also predispose patients to actinomycetes infections. Diabetes was the most com-
mon underlying condition reported in a study conducted in  China36. Other underlying conditions such as 
transplantation, malignancy, and corticosteroid therapy can also predispose patients to actinomycetes infection. 
Healthy individuals are also at risk of actinomycetes infection, as 6.67% of patients in this study did not have 
any underlying disease. Similarly, Hashemi-Shahraki et al. and Yi et al. have diagnosed 21.1% and 44.1% of 
actinomycetes infections in their studies among healthy individuals,  respectively13,36. Therefore, in the presence 
of relevant symptoms, actinomycetes infections should be considered in the differential diagnosis, not only in 
immunocompromised patients but also in immunocompetent individuals.
Nocardia cyriacigeorgica (n = 7, 23.33%) followed by Nocardia otitidiscaviarum (n = 4, 13.33%) were the 
most common identified species in this study which was not in agreement with the previous study in which 
Figure 2.  Pure colonies of isolated species (A) Nocardia cyriacigeorgica, (B) Nocardia kruczakiae, (C) 
Nocardia flavorosea, (D) Nocardia asteroides, (E) Streptomyces griseus, (F) Nocardia cerradoensis, (G) Nocardia 
caishijiensis, (H) Prauserella muralis. 
Figure 3.  Pure colonies of isolated species (A) Nocrdia otitidiscaviarum, (B) Nocardiopsis dassonvillei (C) 
Nocardia cyriacigeorgica, (D) Nocardia ninae, (E) Nocardia.brasiliensis, (F) Rhodococcus erythropolis. 
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Nocardia asteroides (n = 31, 24.41%) and Nocardia cyriacigeorgica (n = 25, 19.69%) were the most common iso-
lated  species13.
Our findings are not in agreement with other countries. For instance, a study conducted on hematopoietic 
stem cell transplant recipients in  Japan37 revealed the Nocardia farcinica (n = 3, 42.86%) as the leading species, 
similar to studies conducted in China with 42.1%40 and 34.78%38 of cases caused by this pathogen. However, in 
the United  States39 and  Spain40, Nocardia nova has been reported as the most common species contributing to 
28% and 29.57% of cases, respectively. Therefore, molecular-based studies providing more precise results are 
needed in all countries for the identification of common and uncommon species in actinomycetes infections. 
Using molecular-based approaches, more unexpected and rare bacterial species are expected to be detected in 
similar cases.
In the present study, infections due to a set of rare actinomycetes were identified. To the best of our knowl-
edge, in this study, Nocardia flavorosea and Rhodococcus erythropolis were reported for the first time in Iran, and 
Nocardiopsis dassonvillei, Streptomyces olivaceus, and Streptomyces griseus for the first time in Asia, and infections 
caused by Nocardia caishijiensis and Prauserella muralis were reported for the first time in the world. We also 
reported the first Asian case of pulmonary infection caused by Nocardia ignorata and the first global cases of 
brain abscess cause by Nocardia ninae and Nocardia neocaledoniensis in this study.
From the treatment point of view, trimethoprim/sulfamethoxazole has been the most common antibiotic 
prescribed in actinomycetes infections, particularly nocardiosis. In the present study, 3 isolates (10.71%) (2 Nocar-
dia otitidiscaviarum and 1 Nocardia flavorosea) were resistant to trimethoprim/sulfamethoxazole. By excluding 
non-Nocardia isolates, this rate was 13.04% among Nocardia species which was higher than the previous report 
in Iran (1.57%)13. The rate of trimethoprim/sulfamethoxazole resistance varies in different studies. While all 
isolates were susceptible to this antibiotic in one  study36, other studies have reported resistance rates of 2%41, 
16.12%42, 21.74%38, and 42%39.
Because of a high rate of the susceptibility of Nocardia species to linezolid and amikacin, both antibiotics have 
been prescribed to treat the infections caused by these  organisms13. High susceptibility of isolates to linezolid in 
this study may imply the effectivity of this antibiotic in similar cases. Also, all Nocardia isolates were susceptible to 
amikacin and only Rhodococcus erythropolis isolates (3.45%) were resistant to this antibiotic. Three trimethoprim/
sulfamethoxazole-resistant isolates were susceptible to linezolid and amikacin in this study demonstrating the 
application of linezolid and amikacin in infections caused by trimethoprim/sulfamethoxazole-resistant isolates. 
However, it is worth pointing out that there are also few studies reporting amikacin and linezolid  resistance40,42,43.
Table 2.  Antimicrobial susceptibility pattern of actinomycetes isolates in this study. IPM imipenem, SXT 
trimethoprim-sulfamethoxazole, MIN minocycline, AMC amoxicillin-clavulanic acid, AMK amikacin, LZD 
linezolid, CIP ciprofloxacin, CRO ceftriaxone, FEP cefepime, DOX doxycycline, cft cefotaxime, P penicillin, 




IPM SXT MIN AMC AMK LZD CIP CRO FEP DOX CFT P GM E AMP PIP CFZ CAZ CAX LEV
Nocardia cyr-
iacigeorgica 7 0 0 14.3 71.5 0 0 100 14.3 28.6 28.6 − − − − − − − − − −
Nocardia otitidis-
caviarum 4 100 50 50 100 0 0 100 100 100 50 − − − − − − − − − −
Nocardia asteroides 3 0 0 100 100 0 0 100 100 100 33.3 − − − − − − − − − −
Nocardia ignorata 2 0 0 0 100 0 0 100 100 100 50 − − − − − − − − − −
Nocardia cerra-
doensis 1 0 0 100 0 0 0 100 0 0 100 − − − − − − − − − −
Nocardia neocal-
edoniensis 1 0 0 100 100 0 0 100 0 100 100 − − − − − − − − − −
Nocardia brasil-
iensis 1 100 0 0 0 0 0 100 100 100 100 − − − − − − − − − −
Nocardia kruc-
zakiae 1 0 0 0 0 0 0 100 0 0 0 − − − − − − − − − −
Nocardia flavorosea 1 100 100 100 100 0 0 0 0 0 100 − − − − − − − − − −
Nocardia caishi-
jiensis 1 0 0 0 100 0 0 0 0 0 0 − − − − − − − − − −
Nocardia ninae 1 0 0 0 100 0 0 0 0 100 100 − − − − − − − − − −
Nocardiopsis das-
sonvillei 2 0 0 0 50 0 0 100 100 100 50 − − − − − − − − − −
Streptomyces 
olivaceus 1 0 0 0 0 0 0 0 100 100 100 − − − − − − − − − −
Streptomyces griseus 1 0 0 0 100 0 0 100 100 0 100 − − − − − − − − − −
Prauserella muralis 1 0 0 0 0 0 0 100 0 100 0 − − − − − − − − − −
Rhodococcus eryth-
ropolis 1 0 − 100 − 100 0 − 100 100 100 0 0 0 0 − − − − − −
Rothia dentocariosa 1 0 − − − − − − − 0 − − − − − 0 0 100 0 0 0
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Also, the int1 and sulf1 were detected in all trimethoprim/sulfamethoxazole-resistant isolates which were 
consistent with previous  findings26. Regarding the non-Nocardia species, the susceptibility patterns were species-
specific. In general, there was no infection with imipenem, trimethoprim/sulfamethoxazole, and linezolid resist-
ance isolates. However, resistance to amikacin was observed in the Rhodococcus erythropolis isolate and with the 
exception of cefazolin, the Rothia dentocariosa isolate was susceptible to the all tested antibiotics.
Based on our findings, there is an urgent need for proper identification and antibiotic susceptibility testing of 
actinomycetes isolates in all regions particularly in vulnerable patients to actinomycetes infections.
Conclusion
Based on the results, a wide range of actinomycetes species can lead to severe infections in vulnerable patients. 
Although Nocardia was reported as the leading genus in this study, emerging new infections due to Nocardia 
ignorata, Nocardiopsis dassonvillei, Nocardia ninae, Rhodococcus erythropolis, Nocardia kruczakiae, Nocardia flavo-
rosea, Streptomyces griseus, Nocardia cerradoensis, Nocardia caishijiensis, Prauserella muralis were also identified. 
Inter-species differences were observed in the antimicrobial resistance pattern in isolates harboring trimetho-
prim/sulfamethoxazole-resistance genes. Precise identification of actinomycetes isolates using molecular-based 
approaches is required for a better understanding of the epidemiology of infection. Although accurate identi-
fication of this group of bacteria is challenging in many laboratories, evaluation of this pathogen particularly 
in patients with underlying medical conditions should not be overlooked. Furthermore, the evaluation of the 
antibiotic resistance pattern of actinomycetes isolates should not be limited to a period of time and continuous 
monitoring is required for the prevention of infection and the improvement of therapeutic approaches.
Data availability
The sequencing data are accessible in the Sequence Read Archive (SRA)/NCBI (http:// www. ncbi. nlm. nih. gov/ 
sra) under accession numbers specified in Table 1.
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